Shareholders approve all proposals put forward by the Board of Directors and re-elect the Chairman and Directors to the board of SynDermix.
ZURICH, SWITZERLAND – 11 June 2019
The Annual General Meeting of the shareholders of SynDermix AG was held today in Zurich, Switzerland, under the chairmanship of Dr. Thomas Mehrling. The shareholders approved all of the motions put forward by the Board of Directors with a significant majority.
Led by the Chairman of the Board, Dr. Thomas Mehrling; Chief Executive Officer, Mr. Dieter Hemmer; Chief Operating Officer, Dr. Jessica Kourniakti and Executive Director of Finance and Controlling, Mr. Rolf Küng, the company presented the key highlights of 2018, as well as the strategic objectives of the company for the coming year. In their presentation to the shareholders, the Chairman and CEO stated that 2018 was a successful year for the Company with significant progress in the development of its technology platforms, particularly its proprietary medical device for the treatment of chronic rhinosinusitis.
Re-election of members of the Board
The Shareholders re-elected each of the Directors to serve for a second term on the Board of SynDermix: Dr. Kevin P. Cox; Dr. Hans Peter Frick; Mr. Dieter Hemmer; Mr. Hermann A. Wirz; Mr. Wolfgang Werlé and Dr. Thomas Mehrling. Thomas Mehrling, who was also re-elected to serve as Chairman of the Board for a second term, commented:
“SynDermix AG has made substantial progress over the past couple of years and the Executive Management, as well as the Board of Directors, sees the company on an excellent path. We are seeing some of the most valuable assets nearing the time of fruition. We, the Management and the Board, are excited about this development. We will put all our efforts into making success happen and we all remain committed to maximising the value of SynDermix to the benefit of the shareholders.”
Annual General Meeting of SynDermix AG, Zurich, 11 June 2019
About SynDermix AG
SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit: www.syndermix.ch
Contact:
SynDermix Management AG
Julian Heinrich
Administration
+41 44 366 40 16